NCT06382051

Modifying PEST for Psoriatic Arthritis Screening

A Multicenter, Prospective, Study to Evaluate the Impact of Modifying the Validated Psoriasis Epidemiology Screening Tool (PEST) on the Potential Diagnosis of Psoriatic Arthritis in Adult Patients With Moderate-to-severe Plaque Psoriasis in Canada ("ScreenX")

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 502 (estimated)
• Sponsor: Novartis Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to assess the impact of adding two questions and pictures to the validated PEST on the potential diagnosis of PsA in participants with moderate-to-severe plaque PsO in Canada.

Detailed description

Patients will be enrolled in the study for up to 66 days and will be asked to fill-out a PsA screening questionnaire at their first dermatologist visit. Patients screening positive for PsA will have a second visit with a rheumatologist where a full PsA diagnosis assessment will be performed. A remote 'end of study' (EOS) visit will be conducted by the dermatologist to document the patient's biologic Disease-Modifying Antirheumatic Drugs (bDMARDs) treatment choice and status.

Conditions

• Plaque Psoriasis
• Psoriatic Arthritis

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	PEST Screening group	PEST Screening group

Timeline

• Start date: 2025-01-23
• Primary completion: 2026-08-28
• Completion: 2026-08-28
• First posted: 2024-04-24
• Last updated: 2026-02-17

Locations

15 sites across 1 country: Canada